Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.800
-0.220-2.44%
Volume:69.22M
Turnover:612.61M
Market Cap:101.39B
PE:23.87
High:9.140
Open:8.950
Low:8.710
Close:9.020
52wk High:11.454
52wk Low:4.463
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.87
T/O Rate:0.60%
Dividend:0.24
Dividend Rate:2.73%
EPS(LYR):0.369
ROE:10.83%
ROA:5.65%
PB:2.69
PE(LYR):23.87
PS:3.41

Loading ...

CSPC Pharmaceutical Group Stock Slips 2.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 09

BRIEF-CSPC Pharmaceutical Says PDE4B Inhibitor Obtains U.S. Clinical Trial Approval

Reuters
·
Mar 06

CSPC PHARMA's Novel High-Selective PDE4B Inhibitor SYH2059 Inhalation Powder Receives US FDA Clearance for Clinical Trials

Stock News
·
Mar 06

CSPC Pharma (01093) Obtains U.S. FDA Approval for Clinical Trials of Highly Selective PDE4B Inhibitor

Bulletin Express
·
Mar 06

CSPC wins FDA approval to start U.S. trials of SYH2059 inhalation powder for pulmonary fibrosis

Reuters
·
Mar 06

CSPC Pharmaceutical - Highly Selective Pde4b Inhibitor (Syh2059 Powder for Inhalation) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Mar 06

CSPC Pharmaceutical Group Stock Advances 3.0% in Hong Kong

Dow Jones
·
Mar 06

Hong Kong Market Analysis: Strait Restrictions Eased, Focus on NPC Press Conference

Stock News
·
Mar 05

CSPC PHARMA (01093) Announces Clinical Trial Approval for Indacaterol-Mometasone Inhalation Treatment

Bulletin Express
·
Mar 05

CSPC PHARMA's Indacaterol/Mometasone Powder for Inhalation Receives Clinical Trial Approval in China

Stock News
·
Mar 05

CSPC Pharma Wins China Clinical Trial Approval for Indacaterol-Mometasone Inhalation Powder

Reuters
·
Mar 05

CSPC Pharmaceutical - - Indacaterol Acetate and Mometasone Furoate Powder for Inhalation Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Mar 05

CSPC Pharma Gets China Nod for Trial of Hemophilia A Drug

MT Newswires Live
·
Mar 04

CSPC PHARMA (01093) Announces Clinical Trial Approval for Emicizumab Injection (SYS6053)

Bulletin Express
·
Mar 04

CSPC PHARMA (01093) Receives Clinical Trial Approval in China for Emicizumab Injection (SYS 6053)

Stock News
·
Mar 04

CSPC wins China clinical trial approval for SYS6053 emicizumab injection

Reuters
·
Mar 04

CSPC Pharmaceutical - Emicizumab Injection (Sys6053) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Mar 04

CSPC Pharmaceutical Group Stock Slides 2.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 04

CSPC PHARMACEUTICAL GROUP LIMITED (01093) Reports No Change in Issued Shares for February 2026

Bulletin Express
·
Mar 03

BRIEF-CSPC Pharmaceutical Says Paclitaxel Protein-Bound Particles Gets Clinical Trial Approval In U.S.

Reuters
·
Mar 02